EZH2 and epithelioid sarcoma: Recent studies have suggested that EZH2 is a potential target in DMG [32, 39], substantiated by the recent FDA approval of Tazemetostat (TazverikTM, Epizyme) for epithelioid sarcoma and follicular lymphoma.